Streetbeat News

Products Services

VERV

Verve Therapeutics has received FDA clearance for its Investigational New Drug application for VERVE-101, a treatment for patients with Heterozygous Familial Hypercholesterolemia.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 10:33 am

TSLA

The past week's noteworthy events include Jared Kushner's praise for Florida's COVID-19 response, details about Tesla's upcoming Cybertruck, Elon Musk's dismissal of an analyst's comment, and skepticism about Cybertruck's 'bulletproof' claim. The Cybertruck details were decoded from the 2024 Model Year VIN on the U.S. auto regulator NHTSA's website, revealing dual motor standard and triple motor performance variants. Elon Musk laughed off Sanford C. Bernstein analyst Toni Sacconaghi's comments likening Tesla to a regular auto company. Investor Jim Chanos questioned the implications of the Cybertruck's stainless steel body in the summer sun.

Portfolio Pulse from Benzinga Neuro

October 23, 2023 | 10:30 am

IDYA

IDEAYA Biosciences has announced the development candidate nomination of a Werner Helicase Inhibitor in partnership with GSK. This development could potentially lead to new treatments in the medical field.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 10:07 am

PODD

Insulet has secured FDA 510(k) clearance for the Omnipod 5 app for iPhone. The Omnipod 5 Automated Insulin Delivery System, which had its full commercial launch in August 2022 in the U.S., previously offered smartphone control for customers using compatible Android devices. The new clearance will allow the system to be controlled from a compatible iPhone.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 10:04 am

AZN

AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the European Union for the treatment of adult patients with advanced non-small cell lung cancer. This approval makes Enhertu the first HER2-directed therapy for patients with HER2-mutant advanced NSCLC in the EU.

Portfolio Pulse from Charles Gross

October 23, 2023 | 9:33 am

GH

Guardant Health has announced initial results from the PEGASUS trial, showing promise for the use of liquid biopsy to guide adjuvant treatment of colon cancer.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 8:32 am

MSFT

Microsoft's CEO, Satya Nadella, emphasized the company's focus on artificial intelligence (AI) and its potential to revolutionize productivity and communication. He compared AI's transformative power to that of cloud computing. However, he also stressed the need for global governance of AI to ensure it does not go beyond human control.

Portfolio Pulse from Benzinga Neuro

October 23, 2023 | 8:21 am

AAPL

Apple Inc. is rumored to be planning the launch of its largest iMac Pro to date, a 32-inch model, in late 2024. This follows the discontinuation of the iMac Pro and the introduction of the 24-inch iMac. The new model is speculated to be equipped with a variant of the M3 processor and targeted towards the 'pro' audience. This move could help Apple solidify its position against competitors offering large, high-performance desktop computers.

Portfolio Pulse from Benzinga Neuro

October 23, 2023 | 8:02 am

GOOG

GOOGL

Google's VP of Cloud’s global AI business, Philip Moyer, has stated that artificial intelligence (AI) will eliminate tedious tasks and make work more satisfying, contradicting fears of widespread job losses. He suggested that generative AI tools such as ChatGPT and Bard will likely boost job satisfaction and productivity. He also mentioned that AI could transform sectors like finance, invoicing, and medicine that involve significant administrative work.

Portfolio Pulse from Benzinga Neuro

October 23, 2023 | 7:52 am

NBTX

Nanobiotix has announced updated preliminary results from its Phase 1 pancreatic cancer trial and new exploratory analysis from its completed Phase 1 head and neck cancer trial. The ongoing Phase 1 study of NBTXR3 in locally advanced pancreatic cancer established a favorable safety profile and recommended dose. An exploratory analysis of completed Study 102 showed a positive correlation between Objective Response to RT-activated NBTXR3 and the extension of Overall Survival for elderly, frail patients with head and neck cancer.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2023 | 7:01 am